La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Chromocell Therapeutics a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Chromocell Therapeutics..

Chromocell Therapeutics (AMEX:CHRO) Azioni, Catena delle Opzioni

Chromocell Therapeutics

Chromocell Therapeutics Corp is a clinical-stage biotechnology company focused on developing and commercializing novel, non-opioid, non-addictive therapeutics to alleviate pain and other associated medical conditions. The company's initial clinical focus is to selectively target the sodium ion-channel known as NaV1.7 for the treatment of various types of chronic neuropathic pain and eye pain. The Company's portfolio also includes pre-clinical work on other sodium channel receptor subtypes, and the company intends to explore these and other compounds for the treatment of additional pain indications.

Chromocell Therapeutics Corporation Common Stock

Chromocell Therapeutics Corp

CHROMOCURE INC by Chromocure, Inc.

ChromaDex Corp

Chromia - United States Dollar

Chronicle

Chrono.tech - United States Dollar

<p><a href="https://x.com/WolfpackReports/status/1853809784731873633" title="https://x.com/WolfpackReports/status/1853809784731873633">https://x.com/WolfpackReports/status/1853809784731873633</a></p>


Trading Ideas

Shares Of MediaAlpha See Volume; Wolfpack Research Thread On X, "We warned everyone about $MAX and the FTC investigation…"

Macro Economic Events

Market Summary

Economics

General

PLTR

Benzinga Market Summary: Global Markets On Watch Amid US Presidential Election, Gold And Oil Move Higher, Palantir Surges On Strong Guidance

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Meta Platforms</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with META, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 31 uncommon options trades for Meta Platforms.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 38% bullish and 35%, bearish.</p>
<p>Out of all of the special options we uncovered, 5 are puts, for a total amount of $641,951, and 26 are calls, for a total amount of $1,896,313.</p>
<h3>Expected Price Movements</h3>
<p>Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $400.0 to $820.0 for Meta Platforms over the last 3 months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of Meta Platforms stands at 2470.58, with a total volume reaching 12,875.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Meta Platforms, situated within the strike price corridor from $400.0 to $820.0, throughout the last 30 days.</p>
<h3>Meta Platforms Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817964_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>META</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/20/24</td>
<td>$11.8</td>
<td>$11.6</td>
<td>$11.68</td>
<td>$540.00</td>
<td>$274.7K</td>
<td>5.6K</td>
<td style="text-align: right;">419</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$11.65</td>
<td>$11.45</td>
<td>$11.56</td>
<td>$610.00</td>
<td>$271.9K</td>
<td>2.3K</td>
<td style="text-align: right;">438</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$82.15</td>
<td>$81.6</td>
<td>$82.15</td>
<td>$500.00</td>
<td>$164.3K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$83.35</td>
<td>$82.15</td>
<td>$82.1</td>
<td>$500.00</td>
<td>$164.2K</td>
<td>12.0K</td>
<td style="text-align: right;">22</td>
</tr>
<tr>
<td>META</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$253.4</td>
<td>$252.2</td>
<td>$253.4</td>
<td>$820.00</td>
<td>$152.0K</td>
<td>11</td>
<td style="text-align: right;">6</td>
</tr>
</tbody>
</table>
</p>
<h3>About Meta Platforms</h3>
<p>Meta is the largest social media company in the world, boasting close to 4 billion monthly active users worldwide. The firm's "Family of Apps," its core business, consists of Facebook, Instagram, Messenger, and WhatsApp. End users can leverage these applications for a variety of different purposes, from keeping in touch with friends to following celebrities and running digital businesses for free. Meta packages customer data, gleaned from its application ecosystem and sells ads to digital advertisers. While the firm has been investing heavily in its Reality Labs business, it remains a very small part of Meta's overall sales.</p>
<p>In light of the recent options history for Meta Platforms, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Where Is Meta Platforms Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 5,457,256, with META's price down by -1.21%, positioned at $560.29.</li>
<li>RSI indicators show the stock to be is currently neutral between overbought and oversold.</li>
<li>Earnings announcement expected in 86 days.</li>
</ul>
<h3>Professional Analyst Ratings for Meta Platforms</h3>
<p>Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $665.0.</p>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; Maintaining their stance, an analyst from Raymond James continues to hold a Strong Buy rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; Maintaining their stance, an analyst from Truist Securities continues to hold a Buy rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; Maintaining their stance, an analyst from Piper Sandler continues to hold a Overweight rating for Meta Platforms, targeting a price of $650.<br />
&#x2A; An analyst from Cantor Fitzgerald has revised its rating downward to Overweight, adjusting the price target to $670.<br />
&#x2A; An analyst from Citigroup persists with their Buy rating on Meta Platforms, maintaining a target price of $705. </p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Meta Platforms options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


Options

Markets

Looking At Meta Platforms's Recent Unusual Options Activity

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Booking Holdings</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BKNG#NASDAQ">BKNG</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with BKNG, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Booking Holdings.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 77% bullish and 0%, bearish.</p>
<p>Out of all of the special options we uncovered, 2 are puts, for a total amount of $53,435, and 7 are calls, for a total amount of $528,728.</p>
<h3>Predicted Price Range</h3>
<p>After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $3600.0 and $5750.0 for Booking Holdings, spanning the last three months.</p>
<h3>Insights into Volume &amp; Open Interest</h3>
<p>Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.</p>
<p>This data can help you track the liquidity and interest for Booking Holdings's options for a given strike price.</p>
<p>Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Booking Holdings's whale activity within a strike price range from $3600.0 to $5750.0 in the last 30 days. </p>
<h3>Booking Holdings Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817959_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1248.0</td>
<td>$1232.0</td>
<td>$1248.0</td>
<td>$3600.00</td>
<td>$124.8K</td>
<td style="text-align: right;">337</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1227.7</td>
<td>$1205.5</td>
<td>$1218.0</td>
<td>$3600.00</td>
<td>$121.8K</td>
<td style="text-align: right;">24</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$467.6</td>
<td>$442.6</td>
<td>$459.59</td>
<td>$4410.00</td>
<td>$91.9K</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$818.9</td>
<td>$800.0</td>
<td>$818.9</td>
<td>$4150.00</td>
<td>$81.8K</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>BKNG</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$492.8</td>
<td>$488.6</td>
<td>$492.8</td>
<td>$4600.00</td>
<td>$49.2K</td>
<td style="text-align: right;">17</td>
<td style="text-align: right;">1</td>
</tr>
</tbody>
</table>
</p>
<h3>About Booking Holdings</h3>
<p>Booking is the world's largest online travel agency by sales, offering booking and payment services for hotel and alternative accommodation rooms, airline tickets, rental cars, restaurant reservations, cruises, experiences, and other vacation packages. The company operates several branded travel booking sites, including Booking.com, Agoda, OpenTable, and Rentalcars.com, and has expanded into travel media with the acquisitions of Kayak and Momondo. Transaction fees for online bookings account for the bulk of revenue and profits.</p>
<p>After a thorough review of the options trading surrounding Booking Holdings, we move to examine the company in more detail. This includes an assessment of its current market status and performance.</p>
<h3>Where Is Booking Holdings Standing Right Now?</h3>
<ul>
<li>With a trading volume of 3,661, the price of BKNG is down by -0.14%, reaching $4770.0.</li>
<li>Current RSI values indicate that the stock is may be overbought.</li>
<li>Next earnings report is scheduled for 107 days from now.</li>
</ul>
<h3>What The Experts Say On Booking Holdings</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $4852.0.</p>
<p><strong>Turn $1000 into $1270 in just 20 days?</strong></p>
<p>20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.<br />
&#x2A; An analyst from Goldman Sachs has decided to maintain their Neutral rating on Booking Holdings, which currently sits at a price target of $4510.<br />
&#x2A; Consistent in their evaluation, an analyst from Morgan Stanley keeps a Equal-Weight rating on Booking Holdings with a target price of $4600.<br />
&#x2A; Consistent in their evaluation, an analyst from RBC Capital keeps a Outperform rating on Booking Holdings with a target price of $5250.<br />
&#x2A; An analyst from Oppenheimer has decided to maintain their Outperform rating on Booking Holdings, which currently sits at a price target of $5000.<br />
&#x2A; Consistent in their evaluation, an analyst from Piper Sandler keeps a Neutral rating on Booking Holdings with a target price of $4900. </p>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Booking Holdings with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


BKNG

A Closer Look at Booking Holdings's Options Market Dynamics

<p>Whales with a lot of money to spend have taken a noticeably bullish stance on <strong>Alibaba Gr Hldgs</strong>.</p>
<p>Looking at options history for Alibaba Gr Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) we detected 13 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 53% of the investors opened trades with bullish expectations and 46% with bearish.</p>
<p>From the overall spotted trades, 7 are puts, for a total amount of $339,810 and 6, calls, for a total amount of $238,260.</p>
<h3>Predicted Price Range</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $90.0 to $115.0 for Alibaba Gr Hldgs during the past quarter. </p>
<h3>Volume &amp; Open Interest Development</h3>
<p>Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Alibaba Gr Hldgs's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Alibaba Gr Hldgs's substantial trades, within a strike price spectrum from $90.0 to $115.0 over the preceding 30 days.</p>
<h3>Alibaba Gr Hldgs Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1730817954_0.png" alt="Options Call Chart" /></p>
<h3>Biggest Options Spotted:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$14.9</td>
<td>$14.65</td>
<td>$14.65</td>
<td>$110.00</td>
<td>$73.2K</td>
<td>6.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$11.45</td>
<td>$11.35</td>
<td>$11.35</td>
<td>$105.00</td>
<td>$56.7K</td>
<td>2.5K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>02/21/25</td>
<td>$14.0</td>
<td>$13.9</td>
<td>$14.0</td>
<td>$110.00</td>
<td>$56.0K</td>
<td>1.6K</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>BABA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$14.0</td>
<td>$13.35</td>
<td>$14.0</td>
<td>$90.00</td>
<td>$56.0K</td>
<td>10.1K</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>BABA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$13.0</td>
<td>$12.7</td>
<td>$13.0</td>
<td>$110.00</td>
<td>$52.0K</td>
<td>4.9K</td>
<td style="text-align: right;">40</td>
</tr>
</tbody>
</table>
</p>
<h3>About Alibaba Gr Hldgs</h3>
<p>Alibaba is the world's largest online and mobile commerce company as measured by gross merchandise volume. It operates China's online marketplaces, including Taobao (consumer-to-consumer) and Tmall (business-to-consumer). The China commerce retail division is the most valuable cash flow-generating business at Alibaba. Additional revenue sources include China commerce wholesale, international commerce retail/wholesale, local consumer services, cloud computing, digital media and entertainment platforms, Cainiao logistics services, and innovation initiatives/other.</p>
<p>Having examined the options trading patterns of Alibaba Gr Hldgs, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance</p>
<h3>Where Is Alibaba Gr Hldgs Standing Right Now?</h3>
<ul>
<li>Currently trading with a volume of 6,120,305, the BABA's price is up by 1.12%, now at $98.67. </li>
<li>RSI readings suggest the stock is currently may be approaching oversold.</li>
<li>Anticipated earnings release is in 10 days.</li>
</ul>
<p><strong>Unusual Options Activity Detected: Smart Money on the Move</strong></p>
<p>Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights"><strong>Click here for access</strong></a>.</p>
<p>Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Alibaba Gr Hldgs options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>


BABA

Check Out What Whales Are Doing With BABA

<p>Deutsche Bank  analyst Melissa Weathers   maintains Lattice Semiconductor (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LSCC#NASDAQ">LSCC</a>) with a Buy and lowers the price target from $56 to $50.</p>


News

Price Target

Analyst Ratings

LSCC

Deutsche Bank Maintains Buy on Lattice Semiconductor, Lowers Price Target to $50

Econ #s

S&P Global Composite PMI For Oct. 54.1 Vs 54.3 Expected; 54.0 Prior

USA S&P Global Services PMI For October 55.0 Vs 55.3 Est.; 55.2 Prior

<p>Deutsche Bank  analyst Bryan Kraft   maintains Fox (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOXA#NASDAQ">FOXA</a>) with a Buy and raises the price target from $42 to $47.</p>


FOXA

Deutsche Bank Maintains Buy on Fox, Raises Price Target to $47

<p>Deutsche Bank  analyst Melissa Weathers   maintains Entegris (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTG#NASDAQ">ENTG</a>) with a Buy and lowers the price target from $145 to $115.</p>


ENTG

Deutsche Bank Maintains Buy on Entegris, Lowers Price Target to $115

<p><strong>Archer-Daniels-Midland Company</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ADM#NYSE">ADM</a>) shares are <a target="_blank" href="https://www.benzinga.com/premarket" rel="noreferrer noopener">trading lower on Tuesday.</a></p>
<p>Yesterday, the company reported third-quarter preliminary adjusted earnings per share of $1.09, <a target="_blank" href="https://www.benzinga.com/pressreleases/24/11/b41733821/adm-reports-preliminary-third-quarter-2024-results" rel="noreferrer noopener">compared with street view of $1.25.</a></p>
<p>The company will restate previously filed fiscal year 2023 Form 10-K and subsequent Forms 10-Q. The company said it has decided to postpone the webcast originally scheduled for November 5 at 9 a.m. Central Time.</p>
<p>The restated filings will include corrections for newly identified errors related to intersegment sales, will reflect the previously-corrected errors, and will provide disclosures applicable to restated segment information.</p>
<p>&#8220;Our third quarter operating results were mixed in a challenging quarter for the business,&#8221; said Chair of the Board and CEO Juan Luciano.</p>
<p>Archer-Daniels-Midland said net earnings are expected to be $18 million, with adjusted net earnings forecasted at $530 million. The company also anticipates a $461 million non-cash charge against GAAP earnings for the third quarter related to its Wilmar equity investment.</p>
<p>&#8220;We are taking the necessary actions to improve performance and drive continued value creation,&#8221; Luciano added.</p>
<p><strong>Also Read: <a target="_blank" href="https://www.benzinga.com/markets/equities/24/11/41736062/boeing-workers-end-seven-week-strike-by-accepting-new-contract-with-major-pay-increases" rel="noreferrer noopener">Boeing Workers End Seven-Week Strike By Accepting New Contract With Major Pay Increases</a></strong></p>
<p>Ag Services and Oilseeds (AS&amp;O) segment operating profit was $480 million during the third quarter of 2024, down 43% compared to the prior-year quarter. Carbohydrate Solutions segment operating profit was $452 million for the third quarter of 2024, down 3% compared to the prior year period. Nutrition segment operating profit was $105 million for the third quarter of 2024, down 19% compared to the prior year period.</p>
<p>&#8220;While Carbohydrate Solutions achieved strong results, our Ag Services and Oilseeds and Nutrition businesses delivered results below expectations, impacted by softer than expected market conditions and the pace of our planned improvement efforts,&#8221; added Luciano.</p>
<p><strong>Outlook</strong>: The company has lowered its 2024 adjusted EPS guidance to a range of $4.50 &#8211; $5.00, down from the previous range of $5.25 &#8211; $6.25, and <a href="https://www.benzinga.com/calendars/guidance">below the $5.23 analyst estimate.</a></p>
<p>The company&#8217;s revised outlook reflects trends in ADM&#8217;s performance to date, legislative and regulatory policy uncertainties, and ongoing headwinds from slower market demand and internal operational challenges.</p>
<p><strong>Price Action: </strong>ADM shares are trading lower by 9.3% to $50.16 at last check Tuesday.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/equities/24/11/41734875/palantirs-ai-gamble-pays-off-as-customer-revenue-from-single-customer-jumps-12x-in-under-8-month" target="_blank" rel="noreferrer noopener">Palantir&#8217;s AI Gamble Pays Off As Customer Revenue From Single Customer Jumps 12x In Under 8 Months — Alex Karp Quips: &#8216;We Should Just Go Home&#8217;</a></strong></li>
</ul>


Earnings

Equities

Guidance

Movers

Archer-Daniels-Midland Stock Dips After Q3 Preliminary Results: Earnings Miss, Guidance Cut Amid Restatements

<p>Lake Street  analyst Eric Martinuzzi   upgrades Brightcove (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BCOV#NASDAQ">BCOV</a>) from Hold to Buy and raises the price target from $2.75 to $3.5.</p>


Upgrades

BCOV

Lake Street Upgrades Brightcove to Buy, Raises Price Target to $3.5

<p>Deutsche Bank  analyst Ross Seymore   maintains Astera Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALAB#NASDAQ">ALAB</a>) with a Buy and raises the price target from $60 to $100.</p>


ALAB

Deutsche Bank Maintains Buy on Astera Labs, Raises Price Target to $100

<p>Deutsche Bank  analyst Brian Bedell   maintains TPG (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TPG#NASDAQ">TPG</a>) with a Buy and raises the price target from $65 to $67.</p>


Deutsche Bank Maintains Buy on TPG, Raises Price Target to $67

<p>HC Wainwright &amp; Co.  analyst Joseph Pantginis   reiterates Krystal Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KRYS#NASDAQ">KRYS</a>) with a Buy and maintains $221 price target.</p>


Reiteration

KRYS

HC Wainwright & Co. Reiterates Buy on Krystal Biotech, Maintains $221 Price Target

WIIM

TDUP

ThredUp shares are trading higher after the company reported better-than-expected Q3 EPS and sales and slightly raised its FY2024 sales guidance.

<p>Deutsche Bank  analyst Brian Bedell   maintains Franklin Resources (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BEN#NYSE">BEN</a>) with a Hold and lowers the price target from $20 to $19.</p>


Deutsche Bank Maintains Hold on Franklin Resources, Lowers Price Target to $19

<p>Deutsche Bank  analyst Brian Bedell   maintains Brookfield Asset Mgmt (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAM#NYSE">BAM</a>) with a Buy and raises the price target from $51 to $56.</p>


Deutsche Bank Maintains Buy on Brookfield Asset Mgmt, Raises Price Target to $56

EGHT

8x8 shares are trading higher after the company reported better-than-expected Q2 EPS and sales.

<p>Deutsche Bank  analyst Brian Bedell   maintains Affiliated Managers Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMG#NYSE">AMG</a>) with a Buy and lowers the price target from $219 to $204.</p>


Deutsche Bank Maintains Buy on Affiliated Managers Group, Lowers Price Target to $204

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p>It&rsquo;s time to dive into the biggest pre-market stock movers with all of the hottest news worth reading about on Wednesday!</p>



<p>Moving stocks this morning are earnings reports, acquisition plans, new drug data and more.</p>



<p>Let&rsquo;s get into that news below!</p>



<h2>Biggest Pre-Market Stock Movers: 10 Top Gainers</h2>



<ol><li><strong>INVO Bioscience</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/invo-stock-quote/"><strong>INVO</strong></a>) stock is rocketing more than 55% alongside its <a href="https://finance.yahoo.com/news/invo-reports-fourth-quarter-full-205900118.html">Q4 earnings report</a>.</li>



<li><strong>Vanda Pharmaceuticals </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/vnda-stock-quote/"><strong>VNDA</strong></a>) shares are soaring over 38% on <a href="https://www.nasdaq.com/press-release/future-pak-confirms-proposal-to-acquire-vanda-pharmaceuticals-for-%247.25-to-%247.75-per">a firm acquisition proposal</a>.</li>



<li><strong>VIA Optronics</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/viao-stock-quote/"><strong>VIAO</strong></a>) stock is surging more than 32% with heavy pre-market trading.</li>



<li><strong>Clene </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/clnn-stock-quote/"><strong>CLNN</strong></a>) shares are rising over 26% on <a href="https://seekingalpha.com/news/4090283-clene-stock-rallies-post-market-on-ms-drug-data?source=content_type%3Areact%7Cfirst_level_url%3Amarket-news%7Csection_asset%3Amain%7Csection%3Aon-the-move">new drug data</a>.</li>



<li><strong>Chromocell Therapeutics</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/chro-stock-quote/"><strong>CHRO</strong></a>) stock is gaining more than 26% on an update to a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239123&amp;type=PDF&amp;symbol=CHRO&amp;cdn=722216dc7f57070dff83767fe9648f9d&amp;companyName=Chromocell+Therapeutics+Corporation&amp;formType=424B3&amp;formDescription=Prospectus+%5BRule+424%28b%29%283%29%5D&amp;dateFiled=2024-04-17">secondary stock offering</a>.</li>



<li><strong>CXApp </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/cxai-stock-quote/"><strong>CXAI</strong></a>) shares are increasing over 26% with its <a href="https://www.marketwatch.com/story/cxapp-shares-rise-29-on-4q-2023-annual-recurring-revenue-growth-13f8abea">latest earnings report</a>.</li>



<li><strong>Seelos Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/seel-stock-quote/"><strong>SEEL</strong></a>) stock is climbing more than 24% without any clear news on Wednesday morning.</li>



<li><strong>Mobile Global Esports</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/mgam-stock-quote/"><strong>MGAM</strong></a>) shares are getting a 22% boost as it <a href="https://investorplace.com/2024/04/why-is-mobile-global-esports-mgam-stock-down-18-today/">prepares for delisting</a>.</li>



<li><strong>Gamer Pakistan</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/gpak-stock-quote/"><strong>GPAK</strong></a>) stock is jumping 21% despite a lack of news today.</li>



<li><strong>Galera Therapeutics</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/grtx-stock-quote/"><strong>GRTX</strong></a>) shares are up over 19% on a <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238318&amp;type=PDF&amp;symbol=GRTX&amp;cdn=6788b7c94daccbdc9a6c5412e270d44c&amp;companyName=Galera+Therapeutics+Inc.&amp;formType=SC+13G&amp;formDescription=Statement+of+acquisition+of+beneficial+ownership+by+individuals&amp;dateFiled=2024-04-16">shareholder stake update</a>.</li>
</ol><h2>10 Top Losers</h2>



<ol><li><strong>Trilogy Metals</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tmq-stock-quote/"><strong>TMQ</strong></a>) stock is plummeting more than 22% <a href="https://www.nasdaq.com/press-release/trilogy-metals-provides-update-on-the-ambler-access-project-2024-04-17">following an update</a> to its Ambler Access Project.</li>



<li><strong>Trio Petroleum</strong> (NYSEMKT:<a href="https://investorplace.com/stock-quotes/tpet-stock-quote/"><strong>TPET</strong></a>) shares are diving over 20% after <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318239194&amp;type=PDF&amp;symbol=TPET&amp;cdn=fb7a5495a316777660288b1087458323&amp;companyName=Trio+Petroleum+Corp.&amp;formType=8-K&amp;formDescription=Current+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-17">securing senior notes and a purchase agreement</a>.</li>



<li><strong>Connexa Sports Technologies</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/yyai-stock-quote/"><strong>YYAI</strong></a>) stock is tumbling more than 18% on Wednesday morning.</li>



<li><strong>Destiny Tech100</strong> (NYSE:<a href="https://investorplace.com/stock-quotes/dxyz-stock-quote/"><strong>DXYZ</strong></a>) shares are taking a close to 18% beating following a rally yesterday.</li>



<li><strong>Ontrak </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/otrk-stock-quote/"><strong>OTRK</strong></a>) stock is sliding over 16% with the release of its <a href="https://finance.yahoo.com/news/ontrak-announces-2023-fourth-quarter-200500612.html">Q4 2023 earnings report</a>.</li>



<li><strong>Dragonfly Energy</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/dfli-stock-quote/"><strong>DFLI</strong></a>) shares are retreating more than 16% <a href="https://investorplace.com/2024/04/why-is-dragonfly-energy-dfli-stock-up-56-today/">after rallying yesterday</a>.</li>



<li><strong>Dynatronics </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/dynt-stock-quote/"><strong>DYNT</strong></a>) stock is pulling back over 16% <a href="https://investorplace.com/2024/04/why-is-dynatronics-dynt-stock-up-93-today/">after rising on Tuesday</a>.</li>



<li><strong>Ryvyl </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/rvyl-stock-quote/"><strong>RVYL</strong></a>) shares are still falling more than 15% despite <a href="https://www.nasdaq.com/press-release/ryvyl-inc.-announces-cancellation-of-proposed-underwritten-public-offering-2024-04-16">canceling a proposed public offering</a>.</li>



<li><strong>Hub Cyber Security</strong> (NASDAQ:<a href="https://investorplace.com/stock-quotes/hubc-stock-quote/"><strong>HUBC</strong></a>) stock is dropping over 14% <a href="https://investorplace.com/2024/04/why-is-hub-cyber-security-hubc-stock-up-35-today/">after a rally yesterday</a>.</li>



<li><strong>iSun </strong>(NASDAQ:<a href="https://investorplace.com/stock-quotes/isun-stock-quote/"><strong>ISUN</strong></a>) shares close out our pre-market stock movers down more than 13% <a href="https://app.quotemedia.com/data/downloadFiling?webmasterId=90423&amp;ref=318238741&amp;type=PDF&amp;symbol=ISUN&amp;cdn=82f25393dbc89b776256155c3f0856b7&amp;companyName=iSun+Inc.&amp;formType=10-K&amp;formDescription=Annual+report+pursuant+to+Section+13+or+15%28d%29&amp;dateFiled=2024-04-16">on an investor update</a>.</li>
</ol><p><em>On the date of publication, William White did not have (either directly or indirectly) any positions in the securities mentioned in this article. The opinions expressed in this article are those of the writer, subject to the&nbsp;InvestorPlace.com&nbsp;</em><a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank"><em>Publishing Guidelines</em></a><em>.</em></p>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2021/01/one-percenter-issues-urgent-warning/?cid=MKT499868&amp;eid=MKT793997">It doesn&rsquo;t matter if you have $500 or $5 million. Do this now.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/2024/04/todays-biggest-pre-market-stock-movers-10-top-gainers-and-losers-on-wednesday-april-17th/">Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

SBFM, BPTH and INDO among pre-market losers

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Chromocell Therapeutics</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/chro-stock-quote/"><strong>CHRO</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Chromocell Therapeutics reported earnings per share of -55 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/chro-stock-earnings-chromocell-therapeutics-for-q1-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q1 2024

Chromocell Therapeutics Corp (CHRO) has provided an update. Chromocell Therapeutics Corporation has recently entered into financial agreements that...

Chromocell Therapeutics Strengthens Finances with Strategic Agreements

Chromocell announces stock repurchase plan

Wall Street Breakfast: The Week Ahead

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Chromocell Therapeutics</strong> (NYSEMKT:<span><a href="https://investorplace.com/stock-quotes/chro-stock-quote/"><strong>CHRO</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Chromocell Therapeutics reported earnings per share of -31 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/chro-stock-earnings-chromocell-therapeutics-for-q2-of-2024/">CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

CHRO Stock Earnings: Chromocell Therapeutics Reported Results for Q2 2024

Chromocell Therapeutics (CHRO) board of directors has authorized an amendment to the Company's existing stock repurchase plan to increase the total...

Chromocell Therapeutics announces amendment to stock repurchase plan

Chromocell announces amendment to stock repurchase plan

Chromocell Therapeutics (CHRO) announced the unveiling of its injectable depot program utilizing peripheral nerve blocks for the treatment of post-...

Chromocell unveils injectable depot program for treating surgical pain

AMAT

ARDT

ARTV

BDTX

CHRO

CLNN

CSCO

CXAI

DFLI

DXYZ

DYNT

EDBL

GOLD

GPAK

GRTX

GTHX

HEPA

HUBC

INVO

ISUN

IVCA

MDIA

MGAM

MNDR

MNDY

NVFY

ONON

OTRK

PAAS

PINS

RVYL

RWOD

SAVA

SAVE

SEEL

SNAP

SPGC

TPET

TWFG

VIAO

VNDA

VZLA

YYAI

ZCMD

Biotech

Interview

This Biotech Is Innovating In Non-Opiod Solutions For Intense Pain

Health Care

Press Releases

Chromocell  Announces Formal Launch of Eye Pain Treatment Program and Hiring of Dr. Simon Chandler

Chromocell Issues Letter to Stockholders from Chief Executive Officer

Chromocell To Present at Alliance Global Partner's Healthcare Company Showcase on Tuesday, May 21, 2024

Chromocell to Participate in the Virtual Investor Lunch Break Series

Financing

Chromocell Announces Stock Repurchase Plan

Chromocell to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Chromocell to Participate in Life Sciences Investor Forum September 19th

Chromocell Announces Amendment to Stock Repurchase Plan

Chromocell to Present at Upcoming Fall Investor Conferences

Chromocell Announces Unveiling of Injectable Depot Program for the Treatment of Surgical Pain

Comments

Chromocell Therapeutics

Chromocell Therapeutics (CHRO) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO